Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.
about
Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacinInsights into Newer Antimicrobial Agents Against Gram-negative BacteriaDelafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacyAntibiotics in the clinical pipeline at the end of 2015.Antibiotics and bacterial resistance in the 21st century.The evolving role of chemical synthesis in antibacterial drug discovery.Newer antibacterials in therapy and clinical trialsDelafloxacin: design, development and potential place in therapyComparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates.Delafloxacin for the treatment of respiratory and skin infections.Prediction of Pharmacokinetics and Penetration of Moxifloxacin in Human with Intra-Abdominal Infection Based on Extrapolated PBPK ModelReversing resistance: The next generation antibacterials.Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes.New antibiotic agents in the pipeline and how they can help overcome microbial resistance.In Vitro Activity of Delafloxacin against Clinical Neisseria gonorrhoeae Isolates and Selection of Gonococcal Delafloxacin Resistance.A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.Advances in MRSA drug discovery: where are we and where do we need to be?Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.Development of novel antibacterial drugs to combat multiple resistant organisms.Novel antibiotics: are we still in the pre-post-antibiotic era?Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Recent Advances in the Rational Design and Optimization of Antibacterial Agents.Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections.Pharmacological characterization of 7-(4-(Piperazin-1-yl)) ciprofloxacin derivatives: antibacterial activity, cellular accumulation, susceptibility to efflux transporters, and intracellular activity.Covalent modification of a ten-residue cationic antimicrobial peptide with levofloxacin.Pharmacodynamic evaluation of the activity of antibiotics against hemin- and menadione-dependent small-colony variants of Staphylococcus aureus in models of extracellular (broth) and intracellular (THP-1 monocytes) infections.New treatment options for lower respiratory tract infections.In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.Influence of the Molecular Weight and Charge of Antibiotics on Their Release Kinetics From Gelatin Nanospheres.[New antibiotics prior to approval: is this the end of the innovative stagnation?].Photodegradation of moxifloxacin in aqueous and organic solvents: a kinetic study.Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin.What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone.Cellular pharmacokinetics and intracellular activity of gepotidacin against Staphylococcus aureus with different resistance phenotypes in models of cultured phagocytic cells.Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties.Safety of Delafloxacin: Focus on Adverse Events of Special Interest
P2860
Q26746616-F1C68281-976F-453A-8528-71F11A8F1860Q26751255-E5B2A8E5-21C8-482F-A453-11872BEAF4B0Q26824268-B743D118-993A-4AA2-88C0-91D802963AB7Q30249262-898A4DD2-90E8-44ED-8A67-7076DB7BE644Q34156349-63A93010-0AE6-44B2-A982-36DD3F0C0230Q34427652-00FDA7D2-B12D-4659-B164-23FD3FD7F7DDQ34488329-35EDDADF-A653-4820-A585-E70BBDC8486FQ34554381-1DED5793-C72F-4D37-BF60-FE0875B1F399Q34596619-9D3FD237-F67F-4847-A7AE-E37F70C6D000Q34667588-35146ADA-3D4F-4682-88F2-4819827C805EQ35127513-3AEE36A2-A733-4A55-BAD9-E2A2717131ACQ35669688-0DE0D362-03C7-4ED4-916F-9886721BCB47Q36785824-BE4EF595-EAE4-4F2B-9EFB-EF0E78653869Q36845895-334A99AB-2887-4959-8184-94D5B2F8DB28Q36887890-4B7694AB-E519-4177-846D-0A29B6C3EED9Q37026608-09B22A30-86F3-42E6-AB04-3566D16F4112Q37112508-23203848-AEC6-437A-8B8D-2E26F812B08CQ38233471-FED5505A-5A78-40BE-BB2F-28F2588ACABBQ38350301-A0D0F1C9-A7DE-4EB6-B2B6-B3ABCF8F11E1Q38363223-DEA69098-EED0-4D24-BF6F-DD972FC59514Q38648594-8C02E929-FBD0-4174-9741-054241595783Q38958278-DFA32AB9-D85E-4A08-BB33-12D8F5B00088Q39031276-BF825574-77E5-4916-8366-A5D29657B313Q39048725-B6B8BD75-61D2-42C8-B3CB-FE8CC22A86A9Q39119349-14821718-A8B9-44A9-A8AB-C6FFF82B3D00Q39352419-3D88BF91-23C1-493D-96CB-4C36BA07AE05Q40111519-04C67B25-340C-43AB-A40C-38ACD1FE3633Q40342746-2458052F-7488-438F-8226-4B8CC157F2AAQ41194442-D33341A5-A746-491B-A813-844AFCB0251AQ41430876-817B048A-76CD-4542-B525-9870F969F50AQ41675300-2AF2A1EA-7300-4AEE-95E6-CB5C415D4600Q41987689-AFFAAA35-FA1C-4179-835B-504490F3BA0EQ42126654-BB7FF3D3-3B71-42D9-A934-64E474BA1B4BQ47736241-DA6005B1-95F1-48C4-A2A8-5A6583EC1BD7Q49874631-F0489897-C2A9-4F65-9340-B5A3F92B6D71Q50065370-57A3BA9C-151F-469F-8BDA-1CD7413C19F8Q52579373-7D56778F-39FC-4734-A90F-BBF056C2469DQ54297668-81D3BB63-F423-4F77-BB4B-3459F27481D3Q55252138-D14297E9-A293-48B7-B122-9AFB83E774FBQ57822396-2B889DF0-E468-40A3-ADBE-033697F4E41E
P2860
Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Contrasting effects of acidic ...... against Staphylococcus aureus.
@ast
Contrasting effects of acidic ...... against Staphylococcus aureus.
@en
Contrasting effects of acidic ...... against Staphylococcus aureus.
@nl
type
label
Contrasting effects of acidic ...... against Staphylococcus aureus.
@ast
Contrasting effects of acidic ...... against Staphylococcus aureus.
@en
Contrasting effects of acidic ...... against Staphylococcus aureus.
@nl
prefLabel
Contrasting effects of acidic ...... against Staphylococcus aureus.
@ast
Contrasting effects of acidic ...... against Staphylococcus aureus.
@en
Contrasting effects of acidic ...... against Staphylococcus aureus.
@nl
P2093
P2860
P356
P1476
Contrasting effects of acidic ...... against Staphylococcus aureus.
@en
P2093
Françoise Van Bambeke
Paul M Tulkens
Sandrine Lemaire
P2860
P304
P356
10.1128/AAC.01201-10
P407
P577
2010-12-06T00:00:00Z